Lancet: Study on the effect of antidepressant mirtazapine on aggressive behavior in patients with dementia

Dementia is one of the most common and serious public health problems of our time

More than 46 million people worldwide suffer from dementia, and this number will double in the next 20 years

There is currently little evidence on safer and effective alternatives to antipsychotic drugs

Mirtazapine is an antidepressant used to treat agitation in dementia, and mirtazapine is an antidepressant used to treat agitation in dementia.

This parallel-group, double-blind, placebo-controlled trial-Mirtazapine Treatment of Agitated Behavior in Dementia (SYMBAD)-was conducted in 26 centers in the UK

The results showed that between January 26, 2017 and March 6, 2020, 204 participants were recruited and randomly grouped

There was no significant difference in the average CMAI scores at 12 weeks between participants who received mirtazapine and participants who received placebo (adjusted average difference -1.

The unadjusted average CMAI score of each treatment group

At the same time, the number of adverse events in the control group (65 of the 102 controls [64%]) was similar to that in the mirtazapine group (67 of the 102 participants who received mirtazapine [66%])

At the same time, the number of adverse events in the control group (65 of the 102 controls [64%]) was similar to that of the mirtazapine group (67 of the 102 participants who received mirtazapine [66%])

In summary, the data in this study does not support the use of mirtazapine as a treatment for agitation in dementia

references:

tudy of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial.

tudy of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial.


Leave a message here